New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
Expanded EBLIS study with up to 12 years of clinical follow-up across all subtypes of breast cancer ...
Source: marketscreener.com
Minetta Liu News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Minetta Liu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Minetta Liu Today - Breaking & Trending Today
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera in Breast Cancer
03.05.2024 - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its personalized and tumor-informed molecular residual disease (MRD) test, ... Seite 1
Source: wallstreet-online.de
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer -April 01, 2024 at 08:06 am EDT
First of its kind study in muscle-invasive urothelial cancer, with both escalation and de-escalation arms Approximately 1,000 patients will be enrolled at more than 300 sites ...
Source: marketscreener.com
Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
Study to evaluate effectiveness of switching treatment to elacestrant in early breast cancer based on the detection of molecular relapse with Signatera™ Approximately 1,900 early-stage breast...
Source: marketscreener.com
Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
08.11.2023 - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be used in a new breast cancer study called TREAT ctDNA (EORTC ... Seite 1
Source: wallstreet-online.de